Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

A giant healthcare company is suing the State of Minnesota over a state law that is supposed to protect small pharmacies in ...

“The FTC staff’s second interim report finds that the three major pharmacy ... he’s glad not to be the only one working to expose PBM practices. He said he launched 46brooklyn in 2018 ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs.

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems ...

A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an interim staff report on pharmacy benefit managers (PBM). Sens.

The Federal Trade Commission's findings underscore the urgency for regulatory oversight to curb exploitative PBM practices and ensure affordable health care access. A report from the Federal Trade ...

The biggest pharmacy benefit managers have made efforts to improve relationships with pharmacies, health insurers, employers ...